Companies › HK inno.N
3 active drug programs in 3 registered trials: 2 Phase 1, 1 Phase 2; Cardiovascular, Immunology.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| IN-115314 Ointment | – | Phase 2 | Mild to Moderate Atopic Dermatitis | – |
| IN-G00002 | – | Phase 1 | Non-valvular Atrial Fibrillation (NVAF) | – |
| IN-R00002 | – | Phase 1 | Non-valvular Atrial Fibrillation (NVAF) | – |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT06725355 | IN-G00002 | Phase 1 | Non-valvular Atrial Fibrillation (NVAF) | Cardiovascular | Oct 2024 |
| NCT06725355 | IN-R00002 | Phase 1 | Non-valvular Atrial Fibrillation (NVAF) | Cardiovascular | Oct 2024 |
| NCT07073677 | IN-115314 Ointment | Phase 2 | Mild to Moderate Atopic Dermatitis | Immunology | Jul 2026 |
No annotated target.
–
Neurimmune CuraSen Therapeutics Seismic Pharmaceuticals Operations Tectonic Operating Company Foresee Pharmaceuticals
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.